Alzamend Change To Liabilities from 2010 to 2025

ALZN Stock  USD 0.89  0.21  30.88%   
Alzamend Neuro Change To Liabilities yearly trend continues to be very stable with very little volatility. Change To Liabilities is likely to grow to about 2.1 M this year. During the period from 2010 to 2025, Alzamend Neuro Change To Liabilities quarterly data regression pattern had range of 2.5 M and standard deviation of  837,153. View All Fundamentals
 
Change To Liabilities  
First Reported
2010-12-31
Previous Quarter
M
Current Value
2.1 M
Quarterly Volatility
837.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Alzamend Neuro financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alzamend Neuro's main balance sheet or income statement drivers, such as Interest Expense of 11 K, Interest Income of 0.0 or Depreciation And Amortization of 43.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Alzamend financial statements analysis is a perfect complement when working with Alzamend Neuro Valuation or Volatility modules.
  
Check out the analysis of Alzamend Neuro Correlation against competitors.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.

Latest Alzamend Neuro's Change To Liabilities Growth Pattern

Below is the plot of the Change To Liabilities of Alzamend Neuro over the last few years. It is Alzamend Neuro's Change To Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alzamend Neuro's overall financial position and show how it may be relating to other accounts over time.
Change To Liabilities10 Years Trend
Slightly volatile
   Change To Liabilities   
       Timeline  

Alzamend Change To Liabilities Regression Statistics

Arithmetic Mean568,812
Coefficient Of Variation147.18
Mean Deviation716,841
Median78,363
Standard Deviation837,153
Sample Variance700.8B
Range2.5M
R-Value0.74
Mean Square Error335.4B
R-Squared0.55
Significance0.001
Slope130,795
Total Sum of Squares10.5T

Alzamend Change To Liabilities History

20252.1 M
2024M
20221.7 M
2021693.6 K
2020-413.2 K
2019-175 K
2018M

About Alzamend Neuro Financial Statements

Alzamend Neuro investors utilize fundamental indicators, such as Change To Liabilities, to predict how Alzamend Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Change To LiabilitiesM2.1 M
When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock:
Check out the analysis of Alzamend Neuro Correlation against competitors.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(134.51)
Return On Assets
(1.22)
Return On Equity
(10.93)
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.